Phase I Study of Rituximab and Tafasitamab with Allogeneic NK Cells for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Led by Paolo Caimi, MD · Updated on 2026-09-09
15
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
This research focuses on people with relapsed or refractory B-cell non-Hodgkins lymphoma NHL that has not responded to at least two prior treatments. It aims to find the recommended dose of allogeneic natural killer NK cells combined with IL-2, Tafasitamab, and Rituximab for treating this condition. NK cells are experimental immune cells that can kill cancer cells and are not yet FDA-approved. The study addresses a need for new therapies as current treatments, including CAR-T cell therapy, have limitations and relapses are common.
Participants will receive lymphodepleting chemotherapy followed by intravenous infusions of allogeneic NK cells, Tafasitamab, Rituximab, and Interleukin-2. The NK cells are given weekly for three weeks, with dose escalation to find the best dose. Rituximab is given once per cycle, and Tafasitamab and IL-2 are given weekly for three weeks. Each treatment cycle lasts 28 days, and participants may complete a second cycle if their disease is stable or improved after the first.
During the study, participants will be monitored for safety and response to treatment over about 12 months. Assessments include tracking dose-limiting toxicities for up to 42 days, adverse events for up to 12 months, and measuring response rates on days 28 and 100. Researchers will also evaluate overall survival and event-free survival for up to a year. Participants will have regular visits for treatment and evaluation throughout the study period.
CONDITIONS
Brief Title
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Research Team
P
Paolo Caimi, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Investigational regimen
Tafasitamab + lenalidomide
What it is
A new investigational combination of the anti‑CD20 antibody rituximab, anti‑CD19 antibody tafasitamab, interleukin‑2 and donor natural killer (NK) cells given after chemotherapy in a dose‑escalation design
An established regimen combining tafasitamab and lenalidomide used in relapsed or refractory diffuse large B‑cell lymphoma for patients not eligible for autologous stem‑cell transplant
Role in trial
Investigational regimen evaluated in a single‑arm, dose‑finding phase I setting
External current‑care treatment option not assessed in this trial
Primary use
Active treatment aiming to establish recommended dose and evaluate safety and preliminary efficacy
Used as an active treatment regimen to produce responses in relapsed/refractory B‑cell NHL patients ineligible for transplant
How it is given or performed
After lymphodepleting chemotherapy (fludarabine and cyclophosphamide), participants receive rituximab, tafasitamab, IL‑2 and escalating doses of NK cells via intravenous infusions
Tafasitamab administered by intravenous infusion with oral lenalidomide on a schedule defined in the L‑MIND protocol
Evidence status
Early safety and dose‑finding data only—no results yet for efficacy
Demonstrated response rates, including overall and complete responses, and durable survival in R/R DLBCL from phase II L‑MIND study
Important risks
Safety profile not yet fully established; risks include unknown adverse events with NK cell infusion and combination immunotherapy
Risks associated with lenalidomide‑related toxicities such as hematologic side effects; manageable with dose modification
Important limitations
Single‑arm, early‑phase trial without direct comparator and small sample size
Evidence comes from single‑arm phase II study; long‑term comparative benefit remains unclear
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Age 18 years or older
Diagnosis of B-cell NHL including diffuse large B-cell lymphoma, high grade B-cell lymphoma, primary mediastinal B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, marginal zone lymphoma, or mantle cell lymphoma
Measurable disease by CT or PET/CT scans or blood tests according to defined criteria
Relapsed or refractory disease after two or more lines of systemic therapy including prior CD19 and/or CD20 therapies
Demonstrated CD19 and/or CD20 expression on post-treatment relapse biopsy if prior CD19 or CD20 therapy was received
ECOG Performance Status of 2 or less
Preserved organ function including bilirubin, liver enzymes, kidney function, cardiac ejection fraction, and oxygen saturation
Ability to understand and willingness to sign informed consent
You will not qualify if you...
Presence of a second active malignancy that could affect toxicity interpretation or survival, except certain skin cancers or carcinoma in situ
Less than 28 days since prior investigational treatment
New York Heart Association class III-IV congestive heart failure
Recent serious cardiovascular events within 6 months
Known HIV infection or AIDS-related illness, except well-controlled HIV with low viral load
Pregnant or breastfeeding women; negative pregnancy test required for women of childbearing potential
Diagnosis of myelodysplastic syndrome on recent bone marrow biopsy
Active hepatitis B or C infection; positive PCR test excludes participation
History of significant central nervous system disorders or active CNS lymphoma involvement
History of active autoimmune disease requiring systemic immunosuppressive medications beyond low-dose steroids within 6 months
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - 28 days per cycle
Participants receive lymphodepleting chemotherapy followed by intravenous infusions of allogeneic NK cells, Rituximab, Tafasitamab, and Interleukin-2. They complete one 28-day treatment cycle and may be eligible for a second cycle based on response.
Weekly infusions during each cycle
Follow-up
Duration - Up to 12 months
Participants are monitored for safety, treatment response, and side effects for up to 12 months after treatment initiation.
Regular follow-up visits as scheduled
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Study of MK-1045 with Rituximab Versus Chemotherapy with Rituximab for Follicular Lymphoma
Phase 2 Open-Label Study Evaluating Safety, Tolerability, and Efficacy of MK-1045 in Blood Cancers Affecting B-Cells
A Prospective, Multi-center Study of Newly Diagnosed Marginal Zone B-cell Lymphoma
Observing Treatment Results and Disease Outcomes
Phase 1 Study of Intratumoral ONM-501 Alone and with Cemiplimab for Advanced Solid Tumors and Lymphomas
Open-Label Study of Oral Tacabrutideg Dose Escalation and Expansion in Patients with B-Cell Malignancies
Phase 3 Study Comparing Orelabrutinib Plus Bendamustine and Rituximab Versus Bendamustine and Rituximab Alone in Patients with Untreated Mantle Cell Lymphoma Aged 60 and Older
Global Study Evaluating New Treatments for Children and Young Adults Up to 25 Years with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Long-Term Safety Study of Oral Pirtobrutinib for Chronic Lymphocytic Leukemia and Non-Hodgkin Lymphoma Participants
Study of Zanubrutinib as Maintenance Therapy for Adults With Mantle Cell Lymphoma in Remission After First-Line Immunochemotherapy
Phase 2 Study of Pirtobrutinib and Glofitamab Combination Therapy for Patients With Relapsed Mantle Cell Lymphoma After BTK Inhibitor Treatment
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Long-Term Survivors after Failure of Chimeric Antigen Receptor T Cell Therapy for Large B Cell Lymphoma: A Role for Allogeneic Hematopoietic Cell Transplantation? A German Lymphoma Alliance and German Registry for Stem Cell Transplantation Analysis.
Patrick Derigs, Wolfgang A Bethge, Isabelle Krämer...